BOEHRINGER-INGELHEIM
14.9.2020 14:03:10 CEST | Business Wire | Press release
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrated BI 425809 has met its primary endpoint. The data showed improvement in cognition in stable adult patients with schizophrenia.1 Central to many everyday tasks, impairment of cognitive function still constitutes a major burden for patients, and no pharmacological treatments are currently approved for cognitive impairment associated with schizophrenia (CIAS). These results presented at the 33rd European College of Neuropsychopharmacology (ECNP) Congress will advance the understanding of how deficits in transmission of signals between nerve cells may contribute to diminishing cognition in people living with schizophrenia.2
The Gly-T1 inhibitor, BI 425809, forms a key component of Boehringer Ingelheim’s Central Nervous System (CNS) research program. The latest trial results, along with an ongoing combination Phase II study of BI 425809 and adjunctive computerized cognitive training, will help determine the direction for BI 425809 in further schizophrenia research.3,4
Prof. W. Wolfgang Fleischhacker, Medical University Innsbruck, Austria: “The outcome of this trial is an important step forward in our understanding of cognition in schizophrenia. Cognitive impairment causes significant challenges for people in their everyday functioning. Patients with schizophrenia struggle with remembering things like birthdays, learning new tasks, concentrating, or making decisions that affect their everyday life. Advancing our understanding of how we might improve these symptoms in schizophrenia is significant for the research community and the patients and families living with this condition.”
The Phase II results of BI 425809 in cognitive impairment associated with schizophrenia are being further evaluated to assess how they will support the continued research and development for the treatment of schizophrenia.
“The trial results for our investigational compound BI 425809 in schizophrenia are encouraging. This is a positive advancement in our mechanistic knowledge of how excitatory neurotransmissions affect aspects of mental illness, aligning with our systematic neurobiological approach to CNS research,” adds Dr Vikas Mohan Sharma, M.D., head of medicine CNS, Retinopathies & Emerging Areas, Boehringer Ingelheim. “We recognize this is important news for people affected by schizophrenia. We are making progress in developing treatments which will not only reveal important advances in our understanding of schizophrenia but also potentially other neuropsychiatric diseases.”
Cognition is a fundamental aspect of everyday life, including problem solving, memory and attention. When affected, people living with poor cognition can have a reduced mental ability to process information, remember straightforward things or perceive other people’s emotions and expressions. These functions are common to many forms of mental disorders such as schizophrenia, Alzheimer’s disease and depression. Finding solutions for cognitive impairment is a key area of Boehringer Ingelheim CNS research.
~ENDS~
For references and notes to editiors, please visit: http://www.boehringer-ingelheim.com/press-release/phase-ii-results-cognitive-impairment-schizophrenia
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005477/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release
Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai
IQOSand Devialet Introduce “Soundsorial Design” Collaboration20.4.2026 10:00:00 CEST | Press release
Exhibition and capsule collection drop at Milan Design Week 2026 Philip Morris International (NYSE: PM) today announced a collaboration between IQOS – the number 1 tobacco heating system1, and Devialet – the French acoustic engineering company, launching “Soundsorial Design” at Milan Design Week 2026. The immersive exhibition is an ethereal landscape of water and light, where sound, movement, and voice become visible across an ever‑changing immersive canvas. A space to push experiential boundaries, where visitors are invited to explore their own frequency as sound transforms into sight.The collaboration celebrates self-expression while connecting a community of over 35 million IQOS users who moved away from cigarettes. Devialet’s mission to give sound its rightful place in our lives, achieved through acoustic breakthroughs, meets IQOS’s bold spirit of being forever curious – the force that pushes the brand to continuously innovate and explore new technologies for a better future. Two p
Europe’s Technology Services Market Accelerates in Q1 on Higher Demand for AI: ISG Index™20.4.2026 10:00:00 CEST | Press release
Combined market up 30%, to record US $12.2 billion, fueled by strong AI-driven IaaS growth Demand for technology services in Europe continued to accelerate in the first quarter, driven by strong demand for the cloud-based infrastructure services needed to power AI, the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm, shows. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows ACV for the combined market (both managed services and cloud-based as-a-service) climbed 30 percent in the first quarter, to a record US $12.2 billion. Sequentially, the market was up 12 percent from its previous high in the fourth quarter. Over the last seven quarters, EMEA’s combined market has risen by double-digits in six of them, averaging 22 percent year-on-year growth in that span. “Europe has clearly turned the corner, as the region
MBRYONICS Announces Further Expansion in Its Customer Base and Manufacturing Facilities to Meet Rapidly Growing Demand20.4.2026 09:00:00 CEST | Press release
MBRYONICS has been expanding its partner and customer ecosystem and has recently been selected by the European Space Agency (ESA) for in-orbit demonstration activities in a team led by Kepler Communications. The €18.6M award is under Element 3 of the High-throughput Optical Network (HydRON) program, a project under ESA’s Optical and Quantum Communications – ScyLight program, within the agency’s Advanced Research in Telecommunications Systems (ARTES). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420035633/en/ MBRYONICS was chosen to be part of this mission following its successful contribution to HydRON Element 2, where the company delivered optical testbed facilities to provide system reliability. In collaboration with Kepler Communications for Element 3, MBRYONICS optical terminal (StarCom), and its ground station test bed, have been selected to demonstrate full interoperability with other optical terminal providers du
Echodyne Named as Radar System for Trust Automation’s $490M Air Force Counter-UAS Engineering Contract20.4.2026 09:00:00 CEST | Press release
EchoShield® radar integrated into Small-Unmanned Air Defense System (SUADS) to deliver on $490M Air Force IDIQ Echodyne, the radar platform company, today announces its inclusion as a primary radar system within Trust Automation’s Small-Unmanned Air Defense System (SUADS) Counter-UAS platform, to be delivered to the U.S. Air Force under a $490M IDIQ contract announced in August 2025. Rapidly Deployable Small-Unmanned Air Defense System (RD-SUADS), Fixed Site Small-Unmanned Air Defense System (FS-SUADS), and Expeditionary Small-Unmanned Air Defense System (EX-SUADS) platforms adhere to the Sensor Open Systems Architecture (SOSA) standard with EchoShield radars being the first fully integrated SOSA solution in the platform. The RD-SUADS platform is a self-contained, self-powered C-UAS system fitted to standard pallet sizes for easy transport via military aircraft, while the FS-SUADS is for deployment at permanent military installations and can be integrated as a group or standalone for d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom